Aclaris Therapeutics filings document a Nasdaq-listed clinical-stage biopharmaceutical issuer developing immuno-inflammatory disease candidates. The record includes 8-K disclosures for quarterly and annual financial results, Regulation FD presentations, clinical pipeline updates for ATI-052 and ATI-2138, and common stock sales under an amended and restated sales agreement.
Proxy materials describe board and shareholder voting matters, executive compensation, equity awards and governance procedures. The filings also identify ACRS common stock, Delaware incorporation, R&D spending, royalty revenue from Lilly and Sun Pharma license agreements and capital-structure disclosures tied to public equity financing.
Vivo Opportunity Fund entities report beneficial ownership stakes in Aclaris Therapeutics, Inc. Vivo Opportunity Fund Holdings, L.P. (via its general partner Vivo Opportunity, LLC) holds 5,966,370 shares of Common Stock, representing 4.3% of the class based on 139,663,680 shares outstanding as of April 30, 2026. Vivo Opportunity Cayman Fund, L.P. (via its general partner Vivo Opportunity Cayman, LLC) holds 700,296 shares, representing 0.5% of the class.
The filing is an Amendment No. 1 to a Schedule 13G/A and lists sole voting and dispositive power for each reporting entity over the stated shares. Signatures show transactions were certified by Kevin Dai as Managing Member on May 12, 2026.
Aclaris Therapeutics reported a larger quarterly loss as it ramped R&D on its immuno-inflammatory pipeline. For the three months ended March 31, 2026, revenue was $2.0 million, mainly from licensing and contract research, while net loss widened to $19.8 million from $15.1 million a year earlier.
Research and development expenses rose to $15.7 million, driven by ATI‑052 Phase 1 programs in atopic dermatitis and asthma, ATI‑9494 preclinical work, and broader discovery investments, partly offset by lower ATI‑2138 costs after a completed Phase 2a trial.
Aclaris strengthened its balance sheet by raising $57.9 million net through an at‑the‑market stock program, ending the quarter with $190.8 million in cash, cash equivalents and marketable securities and an accumulated deficit of $987.6 million. Management believes existing resources will fund operations for more than 12 months, while it continues to seek partnerships and potential royalty monetizations to support development of bosakitug, ATI‑052, ATI‑2138 and ATI‑9494.
Aclaris Therapeutics reported a larger net loss in the first quarter of 2026 as it increased investment in its immuno-inflammatory pipeline, while strengthening its cash position. Net loss was $19.8 million for the quarter, compared with $15.1 million a year earlier.
Total revenue was $2.0 million, up from $1.5 million, mainly from higher royalties under the Lilly and Sun Pharma license agreements. Research and development expenses rose to $15.7 million, driven by clinical work on ATI-052 and manufacturing costs for ATI-9494, partly offset by lower spending on ATI-2138.
In March 2026, Aclaris sold 18.4 million shares of common stock for gross proceeds of $59.8 million. Cash, cash equivalents and marketable securities were $190.8 million as of March 31, 2026, and the company believes this will fund operations through the end of 2028 while it advances programs including ATI-052, ATI-2138, bosakitug and ATI-9494.
Aclaris Therapeutics, Inc. Chief Medical Officer Jesse Wayne Hall reported routine equity compensation activity involving restricted stock units (RSUs). On May 1, 2026, RSUs covering 36,375 shares were converted into common stock at a stated price of $0.00 per share, reflecting a vesting event rather than a market purchase.
On the same date, 9,330 common shares were withheld by Aclaris to cover Hall’s tax withholding obligations tied to the RSU vesting, a non‑market disposition classified as a tax-withholding transaction. After these events, Hall directly held 27,045 shares of common stock and 109,125 RSUs.
Each RSU represents a contingent right to receive one share of Aclaris common stock. The underlying RSUs vest in four equal installments on the first, second, third, and fourth anniversaries of May 1, 2025, subject to Hall’s continued service under the company’s 2024 Inducement Plan.
Aclaris Therapeutics announced positive full top line results from a first‑in‑human Phase 1a trial of ATI‑052, a bispecific antibody targeting TSLP and IL‑4Rα. The study in healthy volunteers tested single doses up to 720 mg and multiple weekly doses up to 480 mg and showed a favorable safety, pharmacokinetic, and pharmacodynamic profile with an estimated half‑life of about 45 days, supporting the potential for dosing as infrequently as every three months.
The company is enrolling Phase 1b proof‑of‑concept trials of ATI‑052 in asthma and atopic dermatitis, with top line data planned for the second half of 2026 and a Phase 2b asthma program expected to start in the fourth quarter of 2026. Aclaris also selected lichen planus (LP) as the lead indication for its oral ITK/JAK3 inhibitor ATI‑2138 and plans a multi‑part Phase 2b basket trial in LP subtypes beginning in the second half of 2026, citing a potential U.S. market opportunity above $1.0 billion and up to $4.0 billion.
Aclaris Therapeutics, Inc. insider-related entity executes open-market sale. On behalf of BML Investment Partners, L.P., a fund associated with ten percent owner Michael Leonard, 300,000 shares of Aclaris common stock were sold in an open-market transaction at $4.53 per share. Following this sale, the fund’s indirect holdings reported as beneficially owned by Mr. Leonard totaled 13,950,000 shares, which he reports with a disclaimer of beneficial ownership except to the extent of his pecuniary interest.
BML Investment Partners, L.P. filed Amendment No. 5 to a Schedule 13G/A reporting beneficial ownership of 13,950,000 shares of Aclaris Therapeutics common stock, representing 9.9% of the class based on 139,663,680 shares outstanding as disclosed on a DEF 14A dated 4/23/2026. The filing states shared voting and dispositive power over these shares and includes a signature block explaining indirect ownership through BML Capital Management, LLC and Braden M. Leonard, with a disclaimer that the reporting persons do not constitute a statutory group under Rule 13d-5(b)(1).
Aclaris Therapeutics, Inc. is soliciting proxies for its virtual 2026 Annual Meeting of Stockholders on June 4, 2026 at 9:00 a.m. Eastern Time. Stockholders of record as of April 14, 2026, holding 139,663,680 shares of common stock, may vote online using a 16-digit control number.
Three items are up for vote: electing two directors (Anand Mehra and Maxine Gowen) for terms ending in 2029, an advisory “say-on-pay” vote on executive compensation, and ratification of PricewaterhouseCoopers LLP as independent auditor for 2026. The board is classified into three classes and currently has eight members, six of whom are independent under Nasdaq rules.
The proxy details 2025 pay for named executive officers, including total compensation of $3,375,591 for CEO Neal Walker, $1,490,790 for CFO Kevin Balthaser, and $1,447,106 for Chief Business Officer James Loerop, combining salary, stock awards, options and bonuses. It also discloses major shareholders such as BML Investment Partners at 10.2% and Biosion, Inc. at 8.1%, outlines board committee responsibilities, insider trading and clawback policies, and explains how votes, broker non-votes and quorum (69,831,841 shares) are determined.
Aclaris Therapeutics ownership disclosure: RA Capital Management, L.P., RA Capital Healthcare Fund, L.P., Peter Kolchinsky and Rajeev Shah report beneficial interests in 7,626,705 shares of Aclaris common stock, representing 6.3% of the class based on 120,595,189 shares outstanding as of January 30, 2026. The filing states the Fund directly holds the 7,626,705 shares; RA Capital serves as investment adviser with shared voting and dispositive power over those shares. The Reporting Persons disclaim status as a group and include a statement that the Fund has delegated voting and disposition authority with a 61-day notice constraint.